Construction work paused at 235 East 42nd Street, David Werner and Metro Loft’s massive office-to-resi conversion in Midtown ...

Pfizer faces challenges from pricing pressures, a 2026 patent cliff, and weak R&D momentum. Click here to find out why I rate ...

TORONTO — Health Canada has authorized updated COVID-19 vaccines by Pfizer and BioNTech and by Moderna for use this ...

Pfizer Inc. (NYSE:PFE) discovers, develops, markets, and sells biopharmaceutical products in the U.S. and internationally. It ...

One of the highest yields you can get right now is from Pfizer (NYSE: PFE). The healthcare giant offers a yield of 6.8%, ...

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

In terms of liquidity and interest, the mean open interest for Pfizer options trades today is 13596.29 with a total volume of 13,024.00. In the following chart, we are able to follow the development ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...